Understanding Peptide Regulation

Approval is always product-specific, indication-specific, and jurisdiction-specific:

• Product-specific — a regulator reviewed a named product from a named manufacturer, with a specific formulation and quality dossier. A substance record, an ingredient name, or a different vendor's vial is not the approved product.

• Indication-specific — approval covers the studied use. A peptide drug approved for one condition is not approved for other uses just because the molecule is the same.

• Jurisdiction-specific — each authority decides for its own territory.

Approval can also be historical rather than current. Sermorelin had FDA-approved products (Geref) that were discontinued in 2008/2009; that history does not make today's research-grade sermorelin an approved drug. Every monograph's status table therefore carries per-row as-of dates, and the approved product label index tracks current label sources.

Regulators work under different statutes, with different evidence reviews, and reach different conclusions:

• United States — the FDA, under the Federal Food, Drug, and Cosmetic Act. See United States regulation.

• European Union and EEA — the EMA runs centralized authorizations; member states authorize other products through national, mutual-recognition, or decentralized routes. See EU and EEA regulation.

• United Kingdom — the MHRA, post-Brexit on its own framework. See United Kingdom regulation.

• Others — Canada, Australia and New Zealand, Japan, and more, linked from the framework page.

Carperitide is the clean example in this catalog: approved in Japan since 1995 for acute heart failure, and not approved in the US, EU, or UK. Non-approval elsewhere is not a hidden scandal or a ban — it usually means no manufacturer sought or obtained authorization there.

Vendors label grey-market peptides "for research use only" or "not for human consumption." Legally, the label wording does not control the classification — intended use does.

Under US law, the definition of a drug (21 USC §321(g)(1)) turns on intended use, not on what the sticker says. If the marketing, claims, or surrounding context imply human therapeutic use, the product can be treated as an unapproved new drug — and selling unapproved new drugs in interstate commerce violates the FDCA. The FDA has issued numerous warning letters to peptide vendors on exactly this theory, and the pattern is similar in other jurisdictions.

So "research use only" is best read as a description of the regulatory vacuum around the product: not reviewed, not manufactured to pharmaceutical standards, not monitored after sale. It is not a safety certification and not a legal safe harbour. Details: United States regulation and Research market vs. approved peptides.

Compounding is the preparation of a medication for an individual patient, and in the US it runs through two legal pathways:

• Section 503A — traditional, patient-specific compounding by pharmacies, with conditional exemptions from the full drug-approval process and limits on which bulk substances may be used.

• Section 503B — registered outsourcing facilities that compound under current good manufacturing practice (CGMP) conditions, subject to bulk-substance and shortage rules.

The critical fact: compounded drugs are not FDA-approved. Neither pathway creates an approval, and neither registration nor an advisory-committee vote converts a bulk substance into an approved product. When the FDA's Pharmacy Compounding Advisory Committee voted in July 2026 to recommend placing BPC-157 on the 503A bulks list, that nonbinding recommendation was not an approval — as the BPC-157 monograph records explicitly.

Compounding rules have been under heightened scrutiny for GLP-1 peptides since 2024, including FDA risk alerts on dosing errors with compounded injectable semaglutide. Other countries regulate pharmacy compounding differently — in the EU it is a member-state matter. See the United States and EU/EEA briefs.

Online peptide supply is inherently cross-border: the seller, website host, payment processor, dispatch point, and buyer can all sit in different jurisdictions, which fragments accountability. Documented patterns and risks include:

• Import enforcement — in the US, unapproved peptides are subject to detention without physical examination under FDA Import Alert #66-78, and the personal-importation policy generally does not cover "research peptide" imports.

• False-claims liability — advertising law (in the US, FTC Act §5) prohibits misleading therapeutic claims, and regulators have warned telehealth companies over compounded-GLP-1 marketing.

• Substandard and falsified products — WHO and INTERPOL document the global problem of illicit, substandard, and falsified medicines in online supply chains; with no regulator overseeing the product, quality risk sits entirely with the buyer.

The full analysis is on the cross-border and online supply page.

Anti-doping rules do not follow drug-approval borders. WADA's Prohibited List applies to athletes under the World Anti-Doping Code in every signatory country, and many peptides are prohibited at all times — unapproved substances under class S0, peptide hormones and growth factors under S2. See the WADA and sport brief.

• Global regulation framework — the hub linking all 16 regulatory zones

• Peptide Safety Fundamentals — what the regulatory vacuum means for product risk

• How to Read a Peptide Monograph — reading the per-jurisdiction status table

• Peptides 0-to-1 — the five entry types, from approved drugs to boundary cases

• Peptide regulation: a world tour — a comparative blog explainer

• FAQ — common regulatory questions

1. Peptides Community — Global peptide regulation framework

2. Peptides Community — United States peptide regulation

3. Peptides Community — European Union and EEA peptide regulation

4. Peptides Community — Cross-border and online supply of peptides

5. Peptides Community — WADA and sport regulation brief